Darkoh Charles, Deaton Magdalena, DuPont Herbert L
Department of Epidemiology, Human Genetics, & Environmental Sciences, Center For Infectious Diseases, School of Public Health, University of Texas Health Science Center, Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Microbiology & Infectious Diseases Program, Houston, TX 77030, USA.
Future Microbiol. 2017 Sep;12(11):975-985. doi: 10.2217/fmb-2017-0024. Epub 2017 Jul 31.
Clostridium difficile infection (CDI) is a major public health problem worldwide. Treatment has become complicated due to the emergence of strains with increased toxigenicity and sporulation rate, together with rampant antibiotics use that disrupts colonization resistance of the colonic microbiota. As a result, there is a critical need for nonantibiotic treatments. Therapies based on inhibiting the toxins, bacterial structures responsible for colonization, virulence and restoration of the gut microbiota are the most important nonantibiotic targets to combat CDI. This report outlines these targets and how they could become the focus of future therapeutic agents. Inhibiting colonization and virulence factors during CDI will disrupt pathogen persistence and decrease exposure to the inflammatory toxins, allowing the immune system to clear the infection.
艰难梭菌感染（CDI）是一个全球性的重大公共卫生问题。由于产毒能力和孢子形成率增加的菌株的出现，以及猖獗的抗生素使用破坏了结肠微生物群的定植抗性，治疗变得复杂。因此，迫切需要非抗生素治疗方法。基于抑制毒素、负责定植的细菌结构、毒力以及恢复肠道微生物群的疗法是对抗CDI最重要的非抗生素靶点。本报告概述了这些靶点以及它们如何成为未来治疗药物的焦点。在CDI期间抑制定植和毒力因子将破坏病原体的持续存在并减少接触炎性毒素，使免疫系统能够清除感染。
